Polatuzumab Vedotin Offers a New Option for Refractory DLBCL

Brittany Lovely
Published: Thursday, Oct 17, 2019
Jeff P. Sharman, MD

Jeff P. Sharman, MD

Frontline therapy is able to cure approximately two-thirds of patients with diffuse large B-cell lymphoma (DLBCL), but that still leaves a large number of patients who experience relapse or refractory disease, according to Jeff Sharman, MD. Exploration of new options in this setting led to the FDA approval of polatuzumab vedotin-piiq (Polivy) in combination with bendamustine and a rituximab product in June 2019.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication